Inactief instrument

Andere talen Regen BioPharma Inc OTC Bulletin Board

Aandelen

US75886M1027

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Regen BioPharma : Material Event - Form 8-K	29/04
Regen BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	24/04
Regen Biopharma, Inc. Files Provisional Patent Application for Accelerating Hematopoietic Reconstitution After an Insult or Chronic Pathology by Administration of Stem Cell Derived Endothelial Progenitor Cells or Endothelial Cells	09/02
Regen BioPharma, Inc. to Present at the Emerging Growth Conference on February 7, 2024	05/02
Regen BioPharma, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	19/01
Regen BioPharma, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	20/11
Regen BioPharma, Inc. Outlines Future Steps in CAR T Program	14/11
Regen BioPharma, Inc Receives Second Phase Confirmatory Data on its Duracar CAR-T Cell Therapy Program	25-10-23
Regen Biopharma, Inc. Expects Second Phase of Confirmatory Study Shortly	18-10-23
Regen BioPharma, Inc. issues Message to the Shareholders from the Chairman And Chief Executive Officer	20-09-23
Studies on Regen Biopharma, Inc.'s Duracar Indicate Potential Suppression of Autoimmunity, Company Retains Contract Research Organization to Conduct Additional Confirmatory Studies	19-09-23
Regen BioPharma, Inc. announced that it has received $0.14875 million in funding	12-09-23
Regen BioPharma, Inc. to Present at the Emerging Growth Conference on August 10, 2023	08-08-23
Regen BioPharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	25-07-23
Regen BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023	18-04-23
REGEN BIOPHARMA INC : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year (form 8-K)	07-02-23
Regen BioPharma Leverages Exosome Technologies to Broaden its Survivin Cancer Immunotherapy Portfolio	23-01-23
REGEN BIOPHARMA INC MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-Q)	19-01-23
Regen BioPharma, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2022	19-01-23
Regen BioPharma, Inc. Announces Board Appointments	07-12-22

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Regen BioPharma Inc OTC Bulletin Board

Aandelen

US75886M1027

Andere talen

Filters